We are live on ! Find out more
TCRX icon

TScan Therapeutics
TCRX

66 hedge funds and large institutions have $272M invested in TScan Therapeutics in 2024 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 22 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

240% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 5

144% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 9

45% more capital invested

Capital invested by funds: $187M → $272M (+$84.9M)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

22% more funds holding

Funds holding: 54 → 66 (+12)

4.82% more ownership

Funds ownership: 73.82% → 78.64% (+4.8%)

Holders
66
Holders Change
+12
Holders Change %
+22.22%
% of All Funds
0.95%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
17
Increased
22
Reduced
9
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
+$3.07M
2
LCM
Laurion Capital Management
New York
+$1.9M
3
Millennium Management
Millennium Management
New York
+$1.84M
4
Goldman Sachs
Goldman Sachs
New York
+$1.45M
5
TAM
Tocqueville Asset Management
New York
+$1.33M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$1.54M
2
6CM
683 Capital Management
New York
-$252K
3
ECM
ExodusPoint Capital Management
New York
-$177K
4
BCM
Bridgeway Capital Management
Texas
-$157K
5
Stifel Financial
Stifel Financial
Missouri
-$120K
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
51
Credit Suisse
Switzerland
$138K +$109K +17,366 New
PFMU
52
Privium Fund Management (UK)
United Kingdom
$127K – – –
OAC
53
OMERS Administration Corp
Ontario, Canada
$113K +$89.3K +14,200 New
JFG
54
Jefferies Financial Group
New York
$96.9K +$76.7K +12,200 New
Citadel Advisors
55
Citadel Advisors
Florida
$90.8K +$71.9K +11,432 New
CAS
56
CTC Alternative Strategies
Illinois
$87.3K +$69.2K +11,000 New
JF
57
Jump Financial
Illinois
$81.7K +$64.7K +10,291 New
Cambridge Investment Research Advisors
58
Cambridge Investment Research Advisors
Iowa
$80K +$63.3K +10,061 New
AWM
59
Aries Wealth Management
Maine
$79.4K – – –
WPW
60
Waldron Private Wealth
Pennsylvania
$79.4K – – –
Lazard Asset Management
61
Lazard Asset Management
New York
$19K -$9.01K -1,432 -36%
UBS Group
62
UBS Group
Switzerland
$15.1K +$3K +477 +33%
Wells Fargo
63
Wells Fargo
California
$2.43K +$31 +5 +2%
Federated Hermes
64
Federated Hermes
Pennsylvania
$445 +$352 +56 New
ACA
65
Atlas Capital Advisors
Wyoming
$142 -$5.52K -878 -98%
Macquarie Group
66
Macquarie Group
Australia
$13 +$10.2K +1,618 New
6CM
67
683 Capital Management
New York
– -$252K -43,198 Closed
VF
68
Virtu Financial
New York
– -$107K -18,418 Closed
Bank of New York Mellon
69
Bank of New York Mellon
New York
– -$97.2K -16,670 Closed
BFM
70
Boothbay Fund Management
New York
– -$77.5K -13,293 Closed
TRCT
71
Tower Research Capital (TRC)
New York
– -$251 -43 Closed
1 2
3

TCRX Hedge Fund Activity: Q1 2024 in Review

66 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q1 2024, worth a combined $272M — up 45% from $187M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new TCRX positions and 5 closed out — a net gain of 12 holders — while 22 added to existing stakes and 9 trimmed.

The largest buyer was Invesco, opening a new position worth an estimated $3.07M. The largest seller was Morgan Stanley, cutting an estimated $1.54M.

  • 66 institutional investors held TScan Therapeutics (TCRX) as of Q1 2024, up from 54 in Q4 2023.
  • Funds reported $272M of TScan Therapeutics stock for Q1 2024, up 45% quarter-over-quarter.
  • 17 funds opened new TScan Therapeutics positions in Q1 2024 and 5 closed out, a net change of +12 holders.
  • The largest TScan Therapeutics buyer in Q1 2024 was Invesco, an estimated $3.07M added.
  • The largest TScan Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $1.54M sold.

Based on aggregated 13F filings for Q1 2024.